Shijiazhuang Pharma Group (CSPC)
Also known as: 39 Lianhuachi East Road, Haidian Dist., Beijing, China | Clinical Medicine Department CSPC R&D Business Division | Conjupro Biotherapeutics Inc, and CSPC | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | CSPC Megalith Biopharmaceutical Co., Ltd. | CSPC Megalith Biopharmaceutical Co.,Ltd. | CSPC-NBP PHARM | CSPC-NBP Pharmaceutical Co., Ltd. | CSPC NBP PHARM CO | CSPC OUYI | CSPC OUYI PHARMA CO LTD | CSPC OUYI PHARM CO | CSPC Pharmaceutical Group Limited | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Department of medicine, CSPC clinical development division | Department of Medicine, CSPC Clinical Development Division | Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2011First marketed drug
Mar 23, 2005First NDA
Dec 19, 2019Last known activity
Dec 30, 2025
Timeline
1990s
- Jan 1, 1992
Shijiazhuang Pharma Group (CSPC)— Founded
2010s
- Jul 5, 2013
donepezil— Marketing Organization
- Dec 19, 2019
levamlodipine— NDA Organization
Drugs by trial phase (123 distinct, 206 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (57 own, 0 via acquisition)
Phase 2 (31 own, 0 via acquisition)
Phase 1 (31 own, 0 via acquisition)
Indications
Studied for
- Arterial Occlusive Diseases
- Arteriosclerosis
- Aspergillosis
- Asthma
- Breast Neoplasms
- Candidiasis
- Candidiasis, Invasive
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Cerebral Infarction
- Cough
- Dementia
- Dementia, Vascular
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Disease
- Esophageal Squamous Cell Carcinoma
- Hypercalcemia
- Influenza, Human
- Invasive Fungal Infections
- Ischemia
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Major Depressive Disorder
- Mycoses
- Neoplasms
- Neutropenia
- Paraneoplastic Syndromes
- Peripheral Arterial Disease
- Peripheral Nervous System Diseases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Recurrence
- Rhinitis
- Rhinitis, Allergic
- Schizophrenia
- Small Cell Lung Carcinoma
- Stroke
- Thrombosis
- Thyroid Diseases
- Thyroid Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Venous Thrombosis
Marketed drugs (22)
Recent trials (50)
- NCT07251062Lead sponsorPhase 2/Phase 3Dec 30, 2025
- NCT07254585Lead sponsorPhase 2Dec 1, 2025
- NCT07256509Lead sponsorPhase 2Nov 30, 2025
- NCT07230626Lead sponsorPhase 3Nov 20, 2025
- NCT07241936Lead sponsorPhase 1/Phase 2Nov 13, 2025
- NCT07116824Lead sponsorPhase 2Sep 15, 2025
- NCT07163364Lead sponsorPhase 3Aug 31, 2025
- NCT06989671Lead sponsorPhase 2Aug 30, 2025
- NCT07165886Lead sponsorPhase 2/Phase 3Aug 29, 2025
- NCT07083505Lead sponsorPhase 2Aug 15, 2025
- NCT07122063Lead sponsorPhase 1/Phase 2Aug 11, 2025
- NCT06947291Lead sponsorPhase 2Jun 4, 2025
- NCT07117435Lead sponsorPhase 1May 13, 2025
- NCT06954818Lead sponsorPhase 1May 10, 2025
- NCT06941142Lead sponsorPhase 1Apr 30, 2025
Details
- Founded
- Hong Kong, CN Jan 1, 1992
- First NDA
- Dec 19, 2019
- Last known activity
- Dec 30, 2025